Bristol-Myers’ melanoma immunotherapy expected to take the spotlight at ASCO

Posted on May 31st, 2010 by

Bristol-Myers Squibb’s (NYSE:BMY) cancer drug ipilimumab is expected to demonstrate durable responses in a limited subset of patients with second-line melanoma, a number of oncologists told Pharmawire. The agent will also be effective as a monotherapy, some noted.

Tags: In the News

You must be logged-in to the site to post a comment.